KT Irfan first Indian athlete to qualify for Tokyo 2020

Sydney, Mar 14: New Zealand pacer Lockie Ferguson has been placed under 24-hour isolation amid the fears of coronavirus after he reported a sore throat following the first ODI of the ongoing three-match series against Australia in Sydney Cricket Ground (SCG) which the hosts won by 71 runs.

"In accordance with recommended health protocols, Lockie Ferguson has been placed in isolation at the team hotel for the next 24 hours after reporting a sore throat at the end of the first ODI," said New Zealand Cricket in a statement.

"Once the test results are received and diagnosed, his return to the team can be determined," it added.

The first ODI of the Chappell-Hadlee series was played in front of empty stands as the spectators were not allowed to be at SCG as a precautionary measure to contain the spread of coronavirus pandemic.

Earlier, Australian fast bowler, Kane Richardson was also tested for the coronavirus, after suffering from a sore throat on Thursday. That saw him left out of the squad for Friday's game but the test was negative.

Tokyo, May 9: As the world continues to grapple with coronavirus pandemic, the organisers of Tokyo Game Show have cancelled 2020 showpiece event.

TGS 2020 was slated to be played from September 24 to September 27 at the Makuhari Messe convention center. However, there now talks going on for holding an online event instead.

According to the Verge, this is the first time that TGS has ever been cancelled since it started in 1996.

TGS 2020 gained more attention because of its status as the last major trade show before the launch of the upcoming next-gen consoles, the Xbox Series X and PlayStation 5.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.